Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

IJPPE > IJPPE Volume 8 > Liver Involvement in Hodgkin's Lymphoma: Types of...
< Back to Volume

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

Full Text PDF

Abstract:

The hepatocytolysis raises questions on following therapeutic conduct when it occurs during chemotherapy for Hodgkin's lymphoma, expression of its liver toxicity. But the onset of primary liver Hodgkin's lymphoma, including the form manifested by acute liver failure, poses even greater problems, as in the case of occurrence of vanishing bile duct syndrome - expression of a paraneoplastic syndrome, hemophagocytic lymphohistiocytosis, peliosis hepatis or association of lymphoma with infection with hepatitis viruses or human immunodeficiency virus or different autoimmune diseases. This review summarizes the clinical experience acquired on the relationship between Hodgkin's lymphoma and liver, from the point of view of clinical manifestations, used treatments and clinical evolution. Suggestions on the course of treatment in patients with Hodgkin's lymphoma and liver damage have been formulated starting from the metabolism and elimination of chemotherapy drugs and taking into account the clinical experience of published clinical trials and cases. This review is a synthesis of knowledge obtained in this field, during the time, of therapeutic possibilities and limits, and formulates potential future milestones for research.

Info:

Periodical:
International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 8)
Pages:
1-15
Citation:
R. G. Mihăilă, "Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 8, pp. 1-15, 2017
Online since:
September 2017
Export:
Distribution:
References:

[1] Cancer Research UK, Hodgkin lymphoma incidence statistics. Information on: http: /www. cancerresearchuk. org/health-professional/hodgkin-lymphoma-incidence-statistics#heading-Five. Accessed: 13. 02. (2016).

[2] International Agency for Research on Cancer, GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide. Information on: http: /globocan. iarc. fr. Accessed: 20. 02. (2016).

[3] J. Ferlay et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, Eur. J. Cancer. 49 (2013) 1374-1403.

[4] International Agency for Research on Cancer, Hodgkin lymphoma. Estimated incidence, mortality & prevalence for both sexes, 2012. Information on: http: /eco. iarc. fr/eucan/Cancer. aspx?Cancer=37. Accessed: 13. 02. (2016).

[5] American Cancer Society, Inc. Surveillance Research, Cancer Facts & Figures 2015. Information on: http: /www. cancer. org/acs/groups/content/@editorial/documents/document/ acspc-044552. pdf. Accessed: 13. 02. (2016).

[6] Z.K. Otrock et al., A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses, Pathol. Oncol. Res. 19 (2013) 715-722.

[7] A. Tomasian et al., Hematologic malignancies of the liver: spectrum of disease, Radiographics. 35 (2015) 71-86.

[8] I. Leeuwenburgh et al., Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy, Eur. J. Gastroenterol. Hepatol. 20 (2008) 145-147.

DOI: https://doi.org/10.1097/meg.0b013e3282b9e6c2

[9] K.M. Bravo-Jaimes, Hemophagocytic lymphohistiocytosis presenting as acute liver failure in a patient with Hodgkin lymphoma: case report and review of the literature, Rev. Gastroenterol. Peru. 35 (2015) 256-257.

[10] A. Kleger et al., First reported case of disease: peliosis hepatis as cardinal symptom of Hodgkin's lymphoma, Oncologist. 14 (2009) 1088-1094.

DOI: https://doi.org/10.1634/theoncologist.2009-0215

[11] E.J. deAndrés-Galiana et al., On the prediction of Hodgkin lymphoma treatment response, Clin. Transl. Oncol. 17 (2015) 612-619.

[12] I. Sakellari et al., Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas, Leuk. Lymphoma. 56 (2015).

DOI: https://doi.org/10.3109/10428194.2015.1028054

[13] M. Orellana et al., Hodgkin lymphoma with hepatic involvement treated with dexametasone, gemcitabine and cisplatin as a bridge to standard therapy: report of one case, Rev. Med. Chil. 140 (2012) 902-905.

[14] K. Thakar et al., CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function, Biomark. Res. 2 (2014) 12.

DOI: https://doi.org/10.1186/2050-7771-2-12

[15] J. McCarthy, A.K. Gopal, Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-Hodgkin and Hodgkin lymphoma with severe hepatic dysfunction, Clin. Lymphoma Myeloma. 9 (2009) 167-170.

DOI: https://doi.org/10.3816/clm.2009.n.039

[16] N.Z. Abbasi et al., Diagnosis and treatment of Hodgkin's lymphoma: at times a challenge, J. Coll. Physicians Surg. Pak. 23 (2013) 752-753.

[17] M.B. Sonbol et al., Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage, Leuk. Lymphoma. 55 (2014) 1815-1821.

DOI: https://doi.org/10.3109/10428194.2013.828349

[18] R. Chakraborty et al., A case of Hodgkin's lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD, J. Blood Med. 6 (2015) 93-97.

DOI: https://doi.org/10.2147/jbm.s67664

[19] I.M. Ghobrial et al., Therapeutic options in patients with lymphoma and severe liver dysfunction, Mayo Clin. Proc. 79 (2004) 169-175.

[20] L. Blackmore et al., Polymorphisms in ABCB11 and ATP8B1 associated with development of severe intrahepatic cholestasis in Hodgkin's lymphoma, J. Clin. Exp. Hepatol. 3 (2013) 159-161.

[21] X. Ortín et al., Acute liver failure as the first manifestation of very late relapsing of Hodgkin's disease, Hematol. Rep. 2 (2010) e5.

[22] J. Ma et al., Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma, Int. J. Clin. Exp. Pathol. 7 (2014) 5045-5050.

[23] Z.M. Li et al., Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites, Chin. J. Cancer. 31 (2012) 342-347.

[24] L.V. Filatova, Features of clinical course of combination chemotherapy for liver involvement in Hodgkin's disease, Vopr. Onkol. 54(2) (2007) 192-203.

[25] M. Schindler et al., Febrile cholestatic jaundice as an initial manifestation of Hodgkin's disease, Medicina (B Aires). 74 (2014) 60-61.

[26] T.A. Eyre et al., Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience, Am. J. Hematol. 90 (2015) E103-110.

DOI: https://doi.org/10.1002/ajh.23989

[27] P. Karmacharya et al., Before it crumbles: Fulminant Hepatic Failure secondary to Hodgkin's Lymphoma, J. Community Hosp. Intern. Med. Perspect. 4 (2014) 25821.

[28] R. López et al., Concurrent liver hodgkin lymphoma and nodular regenerative hyperplasia on an explanted liver with clinical diagnosis of alcoholic cirrhosis at university Hospital Fundación Santa Fe de Bogotá, Case Rep. Pathol. 2014 (2014).

DOI: https://doi.org/10.1155/2014/193802

[29] K.M. Woolf et al., Nodular lymphocyte-predominant Hodgkin lymphoma presenting as fulminant hepatic failure in a pediatric patient: a case report with pathologic, immunophenotypic, and molecular findings, Appl. Immunohistochem. Mol. Morphol. 16 (2008).

DOI: https://doi.org/10.1097/pai.0b013e3180cc3211

[30] Doxorubicin, Résume des caractéristiques du produit. Information on: http: /agence-prd. ansm. sante. fr/php/ecodex/rcp/R0251322. htm.

[31] Bleomicina, Rezumatul caracteristicilor produsului. Information on http: /www. anm. ro/_/_RCP/rcp_4271_09. 02. 12. pdf?anmPage=214&ID=4277. Accessed: 13. 02. (2016).

[32] Vinblastine, Résume des caractéristiques du produit. Information on http: http: /agence-prd. ansm. sante. fr/php/ecodex/rcp/R0156388. htm. Accessed: 12. 02. (2016).

[33] Dacarbazina, Rezumatul caracteristicilor produsului. Information on http: /www. anm. ro/_/_RCP/rcp_4749_25. 06. 12. pdf?anmOrder=Sorter_dci&anmDir=DESC&anmPage=2&ID=6963. Accessed: 13. 02. (2016).

[34] Gemzar, Rezumatul caracteristicilor produsului. Information on http: http: /www. anm. ro/_/_RCP/rcp_1730_24. 06. 09. pdf?anmOrder=Sorter_dci&anmDir=ASC&ID=10056. Accessed: 10. 02. (2016).

[35] Dexamethasone, Rezumatul caracteristicilor produsului. Information on http: /www. anm. ro/_/_RCP/rcp_295_13. 11. 07. pdf?anmOrder=Sorter_cod_atc&anmPage=33&ID=5759. Accessed: 13. 02. (2016).

[36] Cytarabine, Résume des caractéristiques du produit. Information on http: /agence-prd. ansm. sante. fr/php/ecodex/rcp/R0201538. htm. Accessed: 10. 02. (2016).

[37] Cisplatin, Rezumatul caracteristicilor produsului. Information on http: /www. anm. ro/_/_RCP/rcp_6153_31. 01. 06. pdf?anmOrder=rzzpdndi&anmPage=297&ID=5931. Accessed: 13. 02. (2016).

[38] Ifosfamide. Résume des caractéristiques du produit. Information on http: /agence-prd. ansm. sante. fr/php/ecodex/rcp/R0219636. htm. Accessed: 12. 02. (2016).

[39] Carboplatin, https: /www. medicines. org. uk/emc/medicine/622. Accessed: 13. 02. (2016).

[40] Etoposide, Résume des caractéristiques du produit. Information on http: /agence-prd. ansm. sante. fr/php/ecodex/rcp/R0140755. htm. Accessed: 13. 02. (2016).

[41] V. Pejsa et al., No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease, Wien Klin. Wochenschr. 116 (2004) 695-697.

DOI: https://doi.org/10.1007/s00508-004-0247-1

[42] Y. Al-Tonbary et al., Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience, Leuk. Lymphoma. 51 (2010).

DOI: https://doi.org/10.3109/10428191003624249

[43] A. Gupta et al., Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment, Clin. Lymphoma Myeloma Leuk. 16 (2016) e11-14.

DOI: https://doi.org/10.1016/j.clml.2015.11.015

[44] Z. Cao et al., Effect of brentuximab vedotin combined with chlormethine hydrochloride on the treatment of 6 patients with relapsed and refractory Hodgkin lymphoma, Zhonghua Xue Ye Xue Za Zhi. 36(7) (2015) 575-577.

[45] N. Niitsu et al., Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma, Leuk. Lymphoma. 47 (2006) 1908-(1914).

DOI: https://doi.org/10.1080/10428190600688313

[46] A. Stellman, M.M. Loke, S. Mann, Acute liver failure secondary to gemcitabine, BMJ Case Rep. 2010 pii (2010) bcr1220081371.

DOI: https://doi.org/10.1136/bcr.12.2008.1371

[47] M. Takasumi et al., A case of methotrexate-associated lymphoproliferative disorder diagnosed by liver biopsy, Nihon Shokakibyo Gakkai Zasshi. 112 (2015) 115-122.

[48] S. Sachsman et al., Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma, Leuk. Lymphoma. 56 (2015) 2019-(2024).

DOI: https://doi.org/10.3109/10428194.2014.975802

[49] L. Kumar et al., Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome, Natl. Med. J. India. 23 (2010) 330-335.

[50] J.H. Mendler et al., Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma, Ann. Oncol. 19 (2008) 1759-1764.

[51] K. Yoneda et al., Primary biliary cirrhosis following chemotherapy for Hodgkin's lymphoma, Intern. Med. 47 (2008) 419-420.

[52] S. Amer et al., Vanishing bile duct syndrome: a rare cause of jaundice in Hodgkin's lymphoma, Turk. J. Gastroenterol. 24 (2013) 444-446.

[53] A.K. Pass et al., Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature, J. Pediatr. Hematol. Oncol. 30 (2008) 976-980.

[54] K. Nader et al., Vanishing bile duct syndrome as a manifestation of Hodgkin's lymphoma: a case report and review of the literature, Tumori. 99 (2013) e164-168.

[55] A. Aleem et al., Vanishing bile duct syndrome in a Hodgkin's lymphoma patient with fatal outcome despite lymphoma remission, Saudi J. Gastroenterol. 19 (2013) 286-289.

DOI: https://doi.org/10.4103/1319-3767.121037

[56] D. Rota Scalabrini et al., Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature, BMC Res. Notes. 7 (2014) 529.

DOI: https://doi.org/10.1186/1756-0500-7-529

[57] P. Yeh et al., Vanishing bile duct syndrome and immunodeficiency preceding the diagnosis of Hodgkin lymphoma, Intern. Med. J. 44 (2014) 1240-1244.

DOI: https://doi.org/10.1111/imj.12609

[58] K.M. Wong et al., Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review, Kaohsiung J. Med. Sci. 29 (2013) 636-641.

[59] A. Ballonoff et al., Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review, Acta Oncol. 47 (2008) 962-970.

DOI: https://doi.org/10.1080/02841860701644078

[60] B.C. Hope et al., Hodgkin disease relapse discovered at the time of liver transplant for acute liver failure, Pediatr. Transplant. 16 (2012) E10-14.

DOI: https://doi.org/10.1111/j.1399-3046.2010.01380.x

[61] G.M. Ettorre et al., De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008, Transplant Proc. 45 (2013) 2729-2732.

DOI: https://doi.org/10.1016/j.transproceed.2013.07.050

[62] D. Marino et al., Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience, Anticancer Res. 30 (2010) 2383-2391.

[63] D. Sculier et al., Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature, J. Int. AIDS Soc. 17 (2014) 19650.

DOI: https://doi.org/10.7448/ias.17.4.19650

[64] S.J. Flew, K.W. Radcliffe, Haemophagocytic lymphohistiocytosis complicating Hodgkin's lymphoma in an HIV-positive individual, Int. J. STD. AIDS. 21 (2010) 601-603.

DOI: https://doi.org/10.1258/ijsa.2010.009547

[65] H. Hjalgrim, E.A. Engel,. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence, J. Intern. Med. 264 (2008) 537-548.

DOI: https://doi.org/10.1111/j.1365-2796.2008.02031.x

[66] S. Franceschi et al., Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC), Cancer Epidemiol. Biomarkers Prev. 20 (2011) 208-214.

[67] S. Dalia et al., Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies, Leuk. Res. 39 (2015) 1325-1333.

DOI: https://doi.org/10.1016/j.leukres.2015.09.008

[68] Y. Tang et al., Clinical analysis of stages of HBV infection in 100 cases of lymphoma, Asian Pac. J. Cancer Prev. 14 (2013) 959-962.

[69] M.Z. Qiu et al., The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients, Chin. J. Cancer. 29 (2010) 735-740.

[70] J.P. Borde et al., Hepatitis B reactivation following immunosuppressive therapy and screening adherence: a neglected problem?, Dtsch. Med. Wochenschr. 137 (2012) 1458-1462.

[71] M.P. Singh et al., Prolonged jaundice attributed to super infection of hepatitis E virus in a case of resolving leptospirosis, Indian. J. Med. Microbiol. 30 (2012) 103-106.

DOI: https://doi.org/10.4103/0255-0857.93067

[72] P. Begini et al., Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: a case report, Scand. J. Infect. Dis. 43 (2011) 750-752.

[73] P. Ljungman et al., European Conference on Infections in Leukemia. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with haematological malignancies and after SCT, Bone Marrow Transplant. 42 (2008).

DOI: https://doi.org/10.1038/bmt.2008.162

[74] F. Marchesi et al., The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network, Am. J. Hematol. 87 (2012).

DOI: https://doi.org/10.1002/ajh.22214

[75] H. Yang et al., Hepatitis B virus reactivation induced by Brentuximab vedotin in the treatment of Hodgkin lymphoma: a case report and literature review, Zhonghua Xue Ye Xue Za Zhi. 35(10) (2014) 949-950.

[76] I. Wijaya, A. Sanityoso, L.A. Lesmana, Acute liver failure related to chemotherapy, Acta Med. Indones. 44 (2012) 145-149.

[77] C. Schöllkopf et al., Hepatitis C infection and risk of malignant lymphoma, Int. J. Cancer. 122 (2008) 1885-1890.

[78] K. Takahashi et al., Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection, Intern. Med. 51 (2012) 2745-2747.

DOI: https://doi.org/10.2169/internalmedicine.51.8404

[79] S. Vernadakis et al., Long-term outcomes of liver transplant patients with human immunodeficiency virus infection and end-stage-liver-disease: single center experience, Eur. J. Med. Res. 16 (2011) 342-348.

DOI: https://doi.org/10.1186/2047-783x-16-8-342

[80] A.M. Vlădăreanu et al., The impact of hepatitis viruses on chronic lymphoproliferative disorders-preliminary results, J. Med. Life. 3 (2010) 320-329.

[81] E.Y. Loo et al., Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases, Am. J. Surg. Pathol. 37 (2013) 1290-1297.

[82] T. Saitoh et al., Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia, Clin. Lymphoma Myeloma. 8 (2008) 62-64.

DOI: https://doi.org/10.3816/clm.2008.n.007

[83] M.H. El-Naggar et al., Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma, Ann. Pharmacother. 42 (2008) 713-718.

DOI: https://doi.org/10.1345/aph.1k543
Show More Hide
Cited By:

[1] W. Hailan, F. Abou-Tarboush, K. Al-Anazi, A. Ahmad, A. Qasem, M. Farah, "Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice", Drug and Chemical Toxicology, p. 1, 2018

DOI: https://doi.org/10.1080/01480545.2018.1504957